Abbott India spurts after Q4 PAT surges 39% YoY to Rs 211 cr

17 May 2022 , 03:41 PM

Revenue from operations was at Rs 1,255.02 crore for the quarter ended 31 March 2022 as against Rs 1,095.54 crore during the same period in the previous year, registering a growth of 14.56%. The drug makers profit before tax surged 44.49% to Rs 292.30 crore in Q4 FY22 from Rs 201.88 crore in Q4 FY21. On full year basis, the company reported a 15.64% increase in net profit to Rs 798.70 crore on a 14.14% declined in net sales to Rs 4,919.27 crore in FY22 over FY21. Meanwhile, the board of directors of the company has recommended payment of final dividend of Rs 145 and a special dividend of Rs 130 per equity share, for the financial year ended 31 March 2022. Abbott India has a portfolio of science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. Powered by Capital Market – Live News